58 results about "Synovitis" patented technology

A weft yarn for an artificial ligament (1), a weft yarn preparation method, and an artificial ligament (1). The artificial ligament (1) is of a round rod structure; a first woven part (102), an in-joint free filament part (103), and a second woven part (104) which are sequentially connected are formed in the round rod structure in the axial direction thereof; the in-joint free filament part (103) comprises a plurality of weft yarns (201), and the weft yarns (201) extend in the axial direction of the round rod structure; and each weft yarn (201) has a fineness of 1000 D-3000 D / 1-100 F, and a mechanical strength of 75-300 N. By increasing the mechanical strength of a single yarn formed in the in-joint free filament part (103) of the artificial ligament (1), the number of yarns in the in-joint free filament part (103) is decreased. The present invention can eliminate a knee joint synovial membrane inflammatory response caused by chippings of the artificial ligament (1) in the reconstruction process of the artificial ligament (1), reduce the degree of contact adhesion between the in-joint free filament part (103) and the tissue, reduce the probability of adhesion, and solve the clinical problems of the inflammatory response and the prolonged surgery time which are caused by difficult removal due to adhesion of the free filaments and the tissue in the revision surgery.

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention relates to application of a miR-155-5p inhibitor delivered by an exosome of a targeted synovitis macrophage to treatment of osteoarthritis, and belongs to the technical field of biological medicines. According to the scheme, the exosome drug delivery system for targeting the synovial inflammatory macrophages in the osteoarthritis, which contains the miR-155-5p inhibitor, is prepared through a genetic engineering technology, so that the exosome derived from stem cells is targeted to inflammatory synovial tissues, and damaged cartilage tissues are repaired and inflammation is resisted based on the stem cell exosome; compared with the prior art, the application has the advantages that the combined action of inhibiting the osteoarthritis injury and inhibiting the miR-155-5p so as to resist synovitis is realized, the osteoarthritis injury repair can be better applicable, a new scheme for treating the osteoarthritis is provided, a support is provided for clinical transformation, and the application value is extremely high.

The present invention relates to the field of traditional Chinese medicine analysis technology, and more particularly to a method for constructing a characteristic spectrum for synovitis capsules and its application. The method comprises the following steps: 1. preparing a reference solution; 2. preparing a test solution; 3. determining the assay conditions; and 4. importing the chromatogram into a traditional Chinese medicine spectrum to generate a control characteristic spectrum. This characteristic method identifies 13 characteristic peaks, demonstrates high repeatability and precision, and comprehensively and comprehensively displays the chemical composition characteristics of synovitis capsules, enabling comprehensive control of the capsule's pharmaceutical quality.

The invention belongs to the technical field of medicines, and particularly relates to application of BAY-069 in preparation of a medicine for treating rheumatoid arthritis. Through metabonomics research, the inventor finds that the metabolic enzyme BCAT2 is remarkably highly expressed in synovial tissues of an active-stage RA patient and is relatively low in expression in synovial tissues of a remission-stage RA patient. The high expression of the metabolic enzyme BCAT2 is closely related to synovitis and bone destruction. The BAY-069 as a BCAT2 inhibitor can significantly reduce the score of joint inflammation, reduce synovitis and bone destruction, and effectively reduce bone loss. The invention provides an innovative RA metabolism targeted treatment strategy which has high safety and strong targeting property.

The invention belongs to the technical field of traditional Chinese medicine compositions, and provides a powder decoction plaster for treatment and health care of rheumatism bone diseases and a preparation method thereof, the powder decoction plaster comprises the following raw materials by mass: 20-25 parts of ox horn slices, 10-25 parts of light wheat, 20-25 parts of yellow ginger, 20-25 parts of dried ginger, 2-10 parts of notopterygium root, 3-10 parts of sichuanese peppercorn, 0.1-0.5 part of safflower, 0.1-2 parts of cortex acanthopanacis, 0.1-0.5 part of licorice, 1-5 parts of rhizoma cibotii, and 1-5 parts of cortex dictamni. The traditional Chinese medicine disclosed by the invention is decocted into ointment to be applied to an affected part, has the effects of promoting rehabilitation and health, and is used for treatment and health care of lumbar disc herniation, cervical spondylosis, fracture, arthritis, synovitis, hyperostosis, scapulohumeral periarthritis, lumbar disc herniation, sprain and contusion and soft tissue contusion.

The invention provides pain-relieving and stasis-dissipating powder for treating soft tissue and gout, and relates to the technical field of traditional Chinese medicines. The pain-relieving and stasis-dissipating powder for treating soft tissue and gout is prepared from cortex phellodendri, fructus gardeniae, frankincense, myrrh, radix et rhizoma rhei, radix angelicae sinensis, radix angelicae and borneol. The pain-relieving and blood stasis-dissipating powder has the effects of promoting blood circulation to remove blood stasis, relieving swelling and pain, clearing heat, eliminating dampness, removing blood stasis and promoting tissue regeneration, and has a remarkable curative effect on early fracture, soft tissue injury, gout, synovitis and the like.

The invention relates to the technical field of biological medicines, in particular to application of pellicine to preparation of a medicine for treating rheumatoid arthritis. The in-vivo echinaceine can interfere with the pathological process of rheumatoid arthritis in a multi-dimensional manner by inhibiting proliferation, migration and invasion of MH7A cells induced by TNF-alpha, promoting apoptosis of the MH7A cells and down-regulating protein expression of IL-6, MMP-3 and MMP-9. In vivo, the pellicine can relieve joint swelling, synovitis and cartilage injury of adjuvant arthritis rats by inhibiting protein expression of RF, IL-6, MMP-3 and MMP-9. The pellicine has the prospect of being developed into the medicine for treating rheumatoid arthritis.

The application discloses a multi-component synovitis treatment composition based on repairing cartilage tissue and application thereof, and relates to the technical field of biological medicine, and the composition is composed of glucosamine hydrochloride, chondroitin sulfate, dimethyl sulfone and graded molecular weight sodium hyaluronate; the application precisely compounding the graded molecular weight sodium hyaluronate with the glucosamine hydrochloride, the chondroitin sulfate and the dimethyl sulfone according to weight parts, constructs a gradient slow-release and target delivery system of synovitis lesions, specifically inhibits the activity of hyaluronidase in the inflammatory joint cavity by using the dimethyl sulfone, greatly reduces the degradation of the sodium hyaluronate, prolongs the residence time of the active ingredients at the lesion site, realizes immediate analgesia and relieves joint stiffness by quickly forming a lubricating protective film by the high molecular weight sodium hyaluronate, the medium and low molecular weight sodium hyaluronate penetrates the synovial membrane barrier and carries the cartilage repair components to enrich in the cartilage defect area, and the synergistic effect of the components is realized.

Compositions for treatment or prevention of synovitis contain a therapeutically effective amount of at least one of oleuropein, rutin or curcumin and preferably contain at least oleuropin. Methods for treatment or prevention of synovitis include administering such compositions. The compositions can additionally include one or more of quercetin, hydroxytyrosol or vitamin D.

The present disclosure provides improved methods, therapeutic regimens, and systems for treating a disease associated with a pituitary malignancy in a subject, such as treating Cushing Syndrome, or treating one or more symptoms of Cushing Syndrome in subjects, through the inhibition of extracellular diazepam binding inhibitor (DBI) by various methods. The present disclosure also relates to compositions for use and methods in treating synovial inflammation in a subject, the compositions for use and methods comprising an agent that reduces human diazepam binding inhibitor (DBI) activity or expression. The present disclosure also relates to compositions for use and methods in treating degenerative joint disease, joint inflammation, and manifestations thereof in a subject, the compositions for use and methods comprising an agent that reduces human diazepam binding inhibitor (DBI) activity or expression.

The invention discloses a multi-modal data fusion-based rheumatoid arthritis early-stage AI intelligent diagnosis system, belongs to the technical field of medical artificial intelligence, and aims to solve the problems that in the prior art, RA early-stage diagnosis lags behind, the rate of missed diagnosis of serum negative patients is high, and risk assessment lacks quantitative standards. Comprising a multi-source data acquisition module, a data preprocessing module, a cross-modal fusion module, a dynamic time sequence model and a risk assessment module which are connected in sequence, according to the system provided by the invention, a dynamic tracking model of serological change-synovial inflammation-bone structure change is innovatively constructed, and an RA diagnosis window is advanced compared with that of a traditional method (depending on clinical symptoms) by capturing time sequence correlation of the serological change, the synovial inflammation and the bone structure change; aiming at the diagnosis difficulty of serum-negative RA, the system realizes great improvement of diagnosis performance through deep fusion of multi-modal features, serological core indexes, ultrasonic synovial dynamic features and X-ray bone microscopic features.

The present application relates to the field of medicine, and more particularly to a kind of pharmaceutical composition, and the pharmaceutical preparation and application comprising the pharmaceutical composition, the pharmaceutical composition includes ligustrazine nanoparticle and Shujin Huoluo compound composition, ligustrazine nanoparticle includes carrier and ligustrazine loaded in carrier, by ligustrazine nanoparticle and Shujin Huoluo compound composition combined use, play synergistic effect, significantly improve the treatment effect to OA.In addition, both combined use shows significant curative effect in reducing synovial inflammation and repairing chondrocyte apoptosis and reducing pain-related biological indicators, which is of great significance to improve the quality of life of OA patients.

The invention relates to the technical field of body conditioning medicines, in particular to a medicine formula for conditioning a body movement system and a preparation process of the medicine formula. Comprising a main material and an auxiliary material, the main material is prepared by mixing the following raw materials by weight: 15-24 g of white peony root, 2-8 g of licorice, 4-12 g of achyranthes bidentata, 2-8 g of safflower, 5-15 g of dogwood, 5-12 g of prepared rehmannia root, 5-15 g of eucommia ulmoides, 2-10 g of fennel, 4-15 g of fructus aurantii and 15-25 g of folium artemisiae argyi; the auxiliary material is prepared by mixing the following raw materials by weight: 3-7 g of coix seed powder, 1-3 g of small red bean powder, 1-3 g of pea powder, 1-3 g of buckwheat powder, 1-3 g of Chinese yam powder, 1-3 g of soybean powder, 1-3 g of hyacinth bean powder, 8-12 g of Chinese wolfberry and 8-12 g of red dates. The formula has the beneficial effects that the formula is scientifically prepared, the nutrition is balanced, and diseases such as cervical spondylosis, chest, neck, waist and leg pains (chest, neck, waist and legs), protrusion of intervertebral disc, ankylosing spondylitis, arthritis, tennis elbow, rheumatic arthritis, femoral head necrosis, numbness of limbs, arthralgia, synovitis, knee effusion, meniscus injury, hyperostosis, sciatica and varicosity can be conditioned.

The invention relates to the technical field of medicines, in particular to application of nardosinone in preparation of a medicine for treating rheumatoid arthritis. In-vivo animal experiments and in-vitro cell experiments prove that Nardosinone (Nar) has a treatment effect on synovitis caused by rheumatoid arthritis for the first time, and the action mechanism of Nardosinone (Nar) is preliminarily revealed. The invention provides a basis for exploring wide application of Nar in other inflammatory diseases which play a key role in mitochondrial autophagy, and provides a technical support for research and development of novel rheumatoid arthritis treatment medicines.

The application provides a construction method and a content determination method of a synovitis preparation characteristic spectrum, and belongs to the technical field of drug detection. The construction method is that a test sample solution is prepared by using the synovitis preparation, then acetonitrile-0.08-0.12wt% formic acid aqueous solution is used as a mobile phase, high performance liquid chromatography detection is carried out, the characteristic spectrum of the synovitis preparation is obtained, and the content of components in the synovitis preparation is further determined. The method can comprehensively cover the key active components of core medicinal materials in the prescription of the synovitis preparation, realizes the synchronous detection of multiple categories and multiple target components, and completely solves the defects of single quality control index and incomplete coverage in the prior art.

The invention discloses a Jinhuang powder external application paste and application thereof in preparation of drugs for treating gonitis synovitis, the external application paste is prepared from ten traditional Chinese medicines including turmeric, rheum officinale, golden cypress, radix angelicae, rhizoma arisaematis, pericarpium citri reticulatae, rhizoma atractylodis, mangnolia officinalis, liquorice and radices trichosanthis, honey, edible vegetable oil, paraffin oil and water through a specific emulsification process, the pH value is 6.0-7.0, and the viscosity is 3000-5000 mPa.s; standard random control clinical tests prove that the total effective rate of the external application ointment for treating gonarthromeningitis reaches 99.04%, the Lyshilm score is improved by 30.2 score, the VAS score is reduced by 5.39 score and is greatly superior to that of a diclofenac sodium control group, the adverse reaction occurrence rate is only 3.85%, the levels of serum TNF-alpha, IL-1beta and IL-6 and the synovial thickness can be greatly reduced, and the external application ointment has a good clinical application prospect. The method is suitable for K-L grading I-II and postoperative rehabilitation patients.

This invention relates to the field of traditional Chinese medicine preparations, and discloses a Tongli capsule and its preparation process, comprising the following raw materials: Eupolyphaga sinensis, processed Arisaema heterophyllum, vinegar-processed frankincense, vinegar-processed myrrh, dragon bone, Angelica dahurica, Lysimachia christinae, safflower, Notopterygium incisum, Angelica sinensis, Saposhnikovia divaricata, Cimicifuga foetida, Ligusticum chuanxiong, and Acorus tatarinowii; wherein, the raw materials are dried, pulverized, mixed, and then filled into capsule shells to form capsules. This Tongli capsule, using a total of fourteen traditional Chinese medicines as raw materials, follows the treatment principles of traditional Chinese medicine of dispelling wind and dampness, relaxing muscles and tendons, and promoting blood circulation and removing blood stasis. It has significant efficacy for late-stage fractures and joint dislocations, joint pain, synovitis, and other diseases caused by wind-cold-dampness obstructing the meridians. Furthermore, the capsule dosage form, with its uniform fine powder contents, makes it convenient to take, provides accurate dosage, has high bioavailability, and improves patient compliance. Compared to decoctions, capsules do not require decocting, making them easier to carry and store; compared to pills and powders, capsules can mask unpleasant odors of the medicine, and disintegrate rapidly, resulting in faster onset of action.

The invention discloses a dual-module delivery system and application thereof in preparation of a medicine for treating osteoarthritis or synovitis. Comprising an articular cavity drug delivery module 1 and an articular cavity drug delivery module 2, the module 1 is a nanoparticle or an exosome or a microsphere wrapping an aging cell scavenger, and the module 2 is a nanoparticle or an exosome or a microsphere wrapping an M2 polarization inducer; the compound is applied to the treatment medicine for osteoarthritis or synovitis, can target senescence synovial fibroblasts and M1 macrophages, combines senescence cell removal with a macrophage reprogramming mechanism, solves the problems of generation of senescence-related secretory phenotypes and inflammatory polarization of macrophages, and has a good application prospect in treatment of osteoarthritis or synovitis. By reducing SASP sources and inflammatory reactions at the same time, vicious circle of senescence-inflammation cascade reactions is broken, stability of the environment in joints is recovered, and the application prospect is extremely high.

The application belongs to the technical field of biological medicine, and discloses application of oridonin in preparation of a medicine for treating rheumatoid arthritis synovitis. For the first time, it is confirmed that oridonin takes glyceraldehyde-3-phosphate dehydrogenase as a direct action target, covalently combines through an α, β-unsaturated ketone, inhibits enzyme activity, blocks abnormal glycolysis of rheumatoid arthritis synovial cells, activates a KEAP1-NRF2 / HO-1 antioxidant anti-inflammatory pathway, inhibits an NF-κB inflammatory signal, and intervenes in a pathological process of rheumatoid arthritis synovitis from multiple dimensions, thereby providing a scientific basis for clinical application and deep development of oridonin against RA synovitis. A medicine composition containing oridonin and application of the medicine composition in preparation of an anti-rheumatoid arthritis synovitis medicine are disclosed. The application has advantages of target point precision, remarkable curative effect, high safety, mechanism innovation and the like, and provides a brand-new scheme for clinical treatment of rheumatoid arthritis synovitis.

This invention discloses a neutralizing nanobody targeting soluble interleukin-17 receptor D (sIL-17RD), its preparation method, and its applications. The heavy chain variable region (VHH) of this nanobody contains a heavy chain complementarity-determining region 3 (CDR-H3) that specifically binds to sIL-17RD, with a length of 10 amino acids and containing 2–6 lysine residues. This invention provides four nanobodies: CQ5, CQ13, CQ11, and CQ6, corresponding to well-defined CDR-H1, CDR-H2, and CDR-H3 sequence combinations. This nanobody can specifically bind to and neutralize the biological activity of sIL-17RD, reducing chondrocyte death, promoting proliferation, and maintaining extracellular matrix homeostasis by inhibiting the P2rx7-NLRP3 inflammasome-mediated chondrocyte pyroptosis pathway. This invention also protects the nucleic acid encoding this nanobody, the recombinant expression vector, the host cell, the pharmaceutical composition, and the preparation method. The nanobodies described can be used to prepare drugs for the prevention and treatment of inflammatory osteoarthritis and other osteoarthritis. They can inhibit synovitis, reverse cartilage and subchondral bone degeneration, and relieve pain, showing promising application prospects.

This invention provides an in vitro model of synovitis simulating rheumatoid arthritis and its construction method. The method utilizes a three-channel microfluidic chip as a carrier to perform a 3D co-culture model of synovial fibroblasts, macrophages, and vascular endothelial cells. The construction method provided by this invention enables 3D culture of these three cell types, providing results closer to in vivo realities for subsequent drug screening and efficacy evaluation. This method, without adding additional stimuli, simultaneously cultures the three cell types, achieving in vitro simulation of synovial inflammation through cell-cell interactions, which is significant for a deeper understanding of the roles of different cells in the disease.

The application discloses a paeonol-loaded plant nanovesicle and application thereof in preparation of a medicine for regulating rheumatoid arthritis; the plant nanovesicle takes gardenia-derived exosome as a carrier, loads paeonol through an ultrasonic method, and is modified with a cyclic peptide RGD and a CD47 mimetic peptide on the surface, so that the plant nanovesicle can not only avoid being removed by macrophages, but also can penetrate a synovial vascular barrier and a dense extracellular matrix and be accurately delivered to an inflammatory synovial tissue, the delivery system effectively improves the stability and bioavailability of paeonol, can down-regulate a MALAT1 related signal path, inhibit abnormal activation of ERK / MAPK, and significantly reduce the expression of inflammatory factors such as IL-2, IL-6 and TNF-alpha, thereby relieving synovial inflammation of rheumatoid arthritis; the application has high targeting, long circulation, low immunogenicity and multi-dosage form adaptability, provides a novel delivery strategy of a safe and efficient active ingredient of traditional Chinese medicine, and has a wide application prospect.

The present invention discloses a small nucleic acid targeting the RANKL gene and its use in the treatment of orthopedic diseases. The present invention designs a small nucleic acid drug targeting the RANKL gene and further optimizes the sequence and chemical modification to provide an effective treatment strategy for diseases with high RANKL expression. The small nucleic acid drug targeting the RANKL gene provided by the present invention has great application value in the treatment of orthopedic diseases, especially for the treatment of osteoarthritis, rheumatoid arthritis, psoriatic arthritis, bone damage, osteoporosis, bone destruction, and synovitis, which are closely related to the RANKL gene in orthopedic diseases.

The utility model relates to the technical field of rehabilitation training equipment, and discloses an auxiliary supporting device for joint synovitis rehabilitation, which comprises a bottom frame, the top of the bottom frame is fixedly connected with a first supporting plate and a second supporting plate respectively, the top of the bottom frame is fixedly connected with a supporting block, and the top of the supporting block is fixedly connected with a motor. And the output end of the motor is fixedly connected with a rotating shaft, the other end of the rotating shaft penetrates through the first supporting plate and the second supporting plate to be fixedly connected with a connecting disc, and the outer surface of the connecting disc is rotationally connected with a connecting lantern ring. The device has the following advantages and effects that a worker drives the motor to control the rotating shaft to rotate, so that a device on the rotating shaft is subjected to angle adjustment, the support and the second support reinforce supporting and fixing of the whole device, the working efficiency of the whole device is improved, the convenience of the whole device is improved, and the flexibility of the whole device is enhanced; the labor cost and the working time are saved, and the working efficiency of the whole device is improved.

The present application relates to the technical field of rheumatoid arthritis drugs, and particularly relates to methotrexate-baiji polysaccharide nanoparticles and a preparation method and application thereof.The present application provides methotrexate-baiji polysaccharide nanoparticles, which have a structure shown in formula 1.The nanoparticles are formed by connecting methotrexate and baiji polysaccharide through a disulfide bond, and in theory, can realize drug release in response to high active oxygen stimulation in the microenvironment of rheumatoid arthritis.In addition, the present application researches and proves that the nanoparticles can effectively inhibit the proliferation and migration of fibroblast-like synoviocytes, regulate the polarization of M1 macrophages to M2 macrophages, and reduce synovial inflammation.The methotrexate-baiji polysaccharide nanoparticles of the present application have simple preparation process operation, are convenient to use, and have a good development and utilization prospect.Formula 1

The invention belongs to the technical field of medicines, and particularly relates to application of BCAT2 as a target spot in preparation of a medicine for treating rheumatoid arthritis. Through metabonomics research, the inventor finds that the metabolic enzyme BCAT2 is remarkably highly expressed in synovial tissues of an active-stage RA patient and is relatively low in expression in synovial tissues of a remission-stage RA patient. The high expression of the metabolic enzyme BCAT2 is closely related to synovitis and bone destruction. The BCAT2 inhibitor (telmisartan) can significantly reduce joint inflammation score, reduce synovitis and bone destruction, and effectively reduce bone loss. The invention provides an innovative RA metabolism targeted treatment strategy which has high safety and strong targeting property.

The invention relates to the technical field of rheumatoid arthritis medicines, in particular to methotrexate-bletilla striata polysaccharide nanoparticles as well as a preparation method and application thereof. The invention provides methotrexate-bletilla striata polysaccharide nanoparticles. The methotrexate-bletilla striata polysaccharide nanoparticles have a structure as shown in a formula 1. The nanoparticle is formed by connecting methotrexate and bletilla striata polysaccharide through a disulfide bond, and theoretically, the nanoparticle can respond to high active oxygen stimulation in a rheumatoid arthritis microenvironment to realize drug release. In addition, the research proves that the nanoparticles can effectively inhibit proliferation and migration of fibroblast-like synovial cells, adjust polarization of M1 type macrophages to M2 type macrophages and relieve synovial inflammation. The methotrexate-bletilla striata polysaccharide nanoparticles are simple in preparation process operation and convenient to use, and have good development and utilization prospects. Formula 1

The present invention discloses a multi-component synovitis therapeutic composition based on cartilage tissue repair and a use thereof, relating to the technical field of biomedicine. The composition comprises glucosamine hydrochloride, chondroitin sulfate, dimethyl sulfone, and graded molecular weight sodium hyaluronate. By compounding these components in precise parts by weight, the present invention constructs a gradient sustained-release and targeted delivery system for synovitis lesions. Dimethyl sulfone specifically inhibits hyaluronidase activity in the inflamed joint cavity, significantly reducing sodium hyaluronate degradation and prolonging the retention time of each active ingredient at the lesion site. High molecular weight sodium hyaluronate rapidly forms a lubricating protective film to achieve immediate analgesia and relieve ankylosis, while medium- and low-molecular-weight sodium hyaluronate penetrates the synovial barrier and carries cartilage repair components to the cartilage defect area, thereby achieving synergistic enhancement and comprehensively improving synovitis treatment efficacy.

The application discloses a preparation method and application of a multi-morphology fasudil targeted nanomedicine system for diabetes osteoarthritis, and belongs to the technical field of medicines, and comprises the following steps: 1) weighing free fasudil, dissolving the free fasudil in an organic phase solvent, fully stirring and dissolving, and preparing fasudil organic drug stock solution, which is marked as Fas; 2) slowly adding an acid solution to the Fas; the application takes free fasudil as an active drug, constructs Fas@PB-Sr 2+ The composite nano intermediate is subjected to CAP polypeptide targeted modification to obtain multi-morphology targeted nanoparticles. Through a low-temperature hydrothermal process, drug thermal degradation is avoided, square, rod, spherical and porous mesoporous composite morphologies are generated by regulating raw material ratio and reaction conditions, and cartilage specificity enrichment is realized in combination with the CAP polypeptide, multiple pathological damages such as cartilage wear, synovial inflammation and abnormal vascular hyperplasia of diabetes osteoarthritis are improved, joint local drug residence time is prolonged, and systemic drug toxic side effects are reduced.